Rapid Readouts

Rapid Readouts: Patient-Reported Outcomes from ADAURA

ByRoy S. Herbst, MD, PhD, Yale Cancer Center

February 19th 2021

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for patient-reported outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL

ByMartin Hutchings, MD, PhD, Copenhagen University Hospital

January 28th 2021

Rapid Readouts: Phase 2 JULIET Trial

ByMatthew J. Frigault, MD, Massachusetts General Hospital Cancer Center

January 26th 2021

Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer

ByMaria E. Cabanillas, MD, MD Anderson Cancer Center

January 19th 2021

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

ByMatthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute

January 18th 2021

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

ByPeter Voorhees, MD

January 18th 2021

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

ByCatriona Jamieson, MD, PhD, University of California San Diego

January 15th 2021

Rapid Readouts: Results from the Phase 3 ANDROMEDA Study

ByRaymond L. Comenzo, MD, Tufts Medical Center

January 14th 2021

Rapid Readouts: Five-Year Analysis of MURANO Study

ByMatthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute

December 23rd 2020

Rapid Readouts: Updated Results From KX-ORAX-001 Study

ByDawn L. Hershman, MD, Herbert Irving Comprehensive Cancer Center at Columbia University

December 23rd 2020

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

ByDeepu Madduri, MD, Mount Sinai Hospital

December 23rd 2020

Rapid Readouts: Updated Results From DESTINY-Breast01

BySara A. Hurvitz, MD, University of California, Los Angeles

December 23rd 2020

Rapid Readouts: Momelotinib's Spleen, Symptom, and Anemia Efficacy

BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center

December 10th 2020

Rapid Readouts: Long-Term Results from SIMPLIFY-1 and SIMPLIFY-2

BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center

December 10th 2020

Rapid Readouts: Phase 3 VIALE-A Study

ByVinod Pullarkat, MD, City of Hope Medical Center

December 3rd 2020

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

ByPasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute

November 18th 2020

Rapids Readouts: Phase 3 CheckMate 238 Trial

ByJeffrey Weber, MD, PhD, NYU Langone Health, Perlmutter Cancer Center

October 30th 2020

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

ByCora Sternberg, MD, FACP, Weill Cornell Medicine

October 14th 2020

Rapid Readouts: Phase 3 HERO Trial

ByNeal D. Shore, MD, FACS, Carolina Urologic Research Center

October 8th 2020

Rapid Readouts: Phase 3 CheckMate 9ER Trial

ByRana R. McKay, MD, University of California, San Diego

October 7th 2020

Rapid Readouts: Phase 3 ASCENT Study

ByAditya Bardia, MD, Massachusetts General Hospital Cancer Center

October 5th 2020

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

August 24th 2020

Rapid Readouts: Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX

ByZev A. Wainberg, MD

July 17th 2020

Rapid Readouts: Initial Results of the Phase III BOSTON Study

ByCristina Gasparetto, MD, Duke Cancer Institute

June 29th 2020

Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

ByKathleen N. Moore, MD, Stephenson Cancer Center

June 25th 2020

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

BySuresh S. Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University

June 23rd 2020

Rapid Readouts: Final Analysis of KEYNOTE-189

ByEdward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA

June 23rd 2020

Rapid Readouts: Update of CARTITUDE-1

BySaad Z. Usmani, MD, FACP, Levine Cancer Institute

June 23rd 2020

Rapid Readouts: The TIVO-3 Study of Tivozanib in Metastatic Renal Cell Carcinoma

BySumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

June 19th 2020

Rapid Readouts: CheckMate 9LA

ByMartin Reck, MD, PhD, Lung Clinic Grosshansdorf

June 16th 2020

Rapid Readouts

Rapid Readouts: Patient-Reported Outcomes from ADAURA

Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL

Rapid Readouts: Phase 2 JULIET Trial

Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

Rapid Readouts: Results from the Phase 3 ANDROMEDA Study

Rapid Readouts: Five-Year Analysis of MURANO Study

Rapid Readouts: Updated Results From KX-ORAX-001 Study

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

Rapid Readouts: Updated Results From DESTINY-Breast01

Rapid Readouts: Momelotinib's Spleen, Symptom, and Anemia Efficacy

Rapid Readouts: Long-Term Results from SIMPLIFY-1 and SIMPLIFY-2

Rapid Readouts: Phase 3 VIALE-A Study

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

Rapids Readouts: Phase 3 CheckMate 238 Trial

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

Rapid Readouts: Phase 3 HERO Trial

Rapid Readouts: Phase 3 CheckMate 9ER Trial

Rapid Readouts: Phase 3 ASCENT Study

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

Rapid Readouts: Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX

Rapid Readouts: Initial Results of the Phase III BOSTON Study

Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

Rapid Readouts: Final Analysis of KEYNOTE-189

Rapid Readouts: Update of CARTITUDE-1

Rapid Readouts: The TIVO-3 Study of Tivozanib in Metastatic Renal Cell Carcinoma

Rapid Readouts: CheckMate 9LA

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma

Five Under 5: Top Oncology Videos for the Week of 1/25